NEW YORK (GenomeWeb News) – Nasdaq announced that it has completed its semi-annual ranking of the Nasdaq Biotechnology Index, and as a result Celera will be added to the index as of the opening of trade on Nov. 24.
 
While Celera was added, Decode Genetics and Orchid Cellmark have been dropped from the index.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.